Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919813 | 0.96 | PTGER4 (0.45) | MAPTTRPA1SMN1; SMN2CHRM4SCD | |
| SCHEMBL6483921 | 0.91 | MAPT (0.45) | MAPTCHRM4LMNATP53ALDH1A1 | |
| SCHEMBL6484773 | 0.85 | MEN1 (0.41) | MAPTLMNATP53ALDH1A1MEN1 | |
| SCHEMBL6817760 | 0.81 | MAPT (0.38) | MAPTCHRM4SCDLMNATP53 | |
| SCHEMBL6475923 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2LMNATP53L3MBTL1 | |
| SCHEMBL6817764 | 0.79 | MAPT (0.37) | MAPTCHRM4SCDLMNATP53 | |
| SCHEMBL6475676 | 0.77 | MEN1 (0.39) | MAPTTP53MEN1KMT2A | |
| SCHEMBL6289354 | 0.76 | LMNA (0.46) | MAPTTRPA1SMN1; SMN2CHRM4SCD | |
| SCHEMBL6814150 | 0.75 | TRPA1 (0.51) | MAPTTRPA1SMN1; SMN2CHRM4L3MBTL1 | |
| SCHEMBL6477100 | 0.73 | CHRM4 (0.43) | MAPTTRPA1CHRM4SCDKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPT 4485/4885TRPA1 4030/4885SMN1; SMN2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.